期刊文献+

他莫昔芬对雌激素受体阴性乳腺癌细胞杀伤能力的研究

Killing capability of tamoxifen to estrogen receptor negative breast cancer cells in vitro
原文传递
导出
摘要 目的观察他莫昔芬(TAM)联合MCF-7细胞株上清对MDB—DA231细胞株存活率的影响。方法细胞计数试剂盒(CCK-8)检测TAM对MCF-7和MDA—MB-231杀伤能力的差异;CCK-8及流式细胞仪(FCM)检测MCF-7细胞株上清对MDB-DA231细胞株存活率的影响以及MCF-7细胞株上清联合TAM对MDB-DA231细胞株存活率的影响。结果在15μmol/LTAM培养条件下,MCF-7细胞存活率低于MDA—MB-231细胞存活率[(3.03±0.32)%比(45.06±14.29)%],差异有统计学意义(P〈0.05);在MCF-7细胞上清培养条件下,MDA-MB-231细胞存活率低于培养基对照组[(83.79±2.58)%比(99.99±1.07)%)],差异有统计学意义(P〈0.05);在MCF-7细胞株上清联合TAM培养条件下,MDA—MB-231细胞存活率低于培养基对照组[(1.61±0.15)%比(99.99±1.07)%],差异有统计学意义(P〈0.05)。在15μmol/LTAM培养条件下,MDA—MB-231被抑制在G0~G1期[(59.14±0.39)%比(50.28±0.0.52)%],差异有统计学意义(P〈0.05);在MCF-7细胞上清培养条件下,MDA—MB-231细胞周期无明显变化(P〉0.05);在MCF-7细胞株上清联合TAM培养条件下,MDA—MB-231被抑制在G0-G1期[(60.79±0.67)%比(59.14±0.39)%],差异有统计学意义(P〈0.05)。结论MCF-7细胞上清能够增强TAM对MDA—MB-231细胞株的杀伤能力。 Objective To study the effect of tamoxifen combined with the supematant of MCF-7 cell lines on the survival of MDB-DA231 cell lines in vitro. Methods Cell counting kit-8 (CCK-8) was used to analyze the difference of killing by tamoxifen between 1.0 × 10^5/pore MDA-MB-231 and MCF-7. CCK-8 and flow eytometry (FCM) were used to analyze the killing of the supematant of MCF-7 cell lines to MDB-DA231 cell lines and the killing of tamoxifen combined with the supematant of MCF-7 cell lines to 1.0 × 10^5/pore MDB-DA231 cell lines. Results The survival rate of MCF-7 was lower than that of MDA-MB-231 cultured with 15 μmol/L of tamoxifen [ (3.03 ± 0. 32)% vs. (45.06 ± 14. 29 )% ,P 〈 0. 05 ]. After culture with the supematant of MCF-7 cells, the survival rate of MDA-MB-231 cells was increased [ ( 83.79 ± 2. 58 ) % vs. (99. 99 ± 1.07 ) %, P 〈 0. 05 ]. After culture with tamoxifen combined with the supernatant of MCF-7 cells, the survival rate of MDA-MB-231 cells was significantly increased [ ( 1.61 ± 0. 15)% vs. (99. 99 ± 1.07)% ,P 〈0. 05]. After culture with 15 μmol/L of tamoxifen, the cell cycle of MDA-MB-231 cells was arrested in G0-G1 phase [ ( 59. 14 ± 0. 39 ) % vs. (50. 28 ± 0. 0. 52 ) %, P 〈 0. 05 ]. After culture with the supematant of MCF-7 cells, no eel1 cycle arrest was found in MDA-MB-231 cells (P 〉 0. 05 ). After culture of tamoxifen combined with the supematant of MCF-7 cells, the eel1 cycle of MDA-MB-231 cells was arrested in GO-G1 phase [ ( 60. 79 ± 0. 67 ) % vs. ( 59. 14 ± 0. 39 ) %, P 〈 0. 05 ]. Conclusion The supernatant of MCF-7 cells could enhance the killing ability of tamoxifen to MDA-MB-231 cells.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2014年第5期953-955,共3页 Chinese Journal of Experimental Surgery
关键词 乳腺癌 他莫昔芬 内分泌治疗 Breast cancer Tamoxifen Endocrinotherapy
  • 相关文献

参考文献10

  • 1Coster S, Fallowfield LJ. The impact of endocrine therapy on patients with breast cancer: a review of the literature [ J ]. Breast, 2002, 11 (1) :1-12.
  • 2高德宗,孙靖中,余之刚,唐鲁兵,王成刚,江立玉.γ-干扰素增强他莫昔芬抗ER阴性乳腺癌细胞作用的实验研究[J].中国肿瘤生物治疗杂志,2005,12(3):215-217. 被引量:3
  • 3Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for preven- tion of breast cancer: current status of the national surgical adjuvant breast and bowel project P-1 study[ J]. J Natl Cancer Inst,2005,97 (22) : 1652-1662.
  • 4Powles TJ, Ashley S, Tidy A, et al. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer preven- tion trial[ J]. J Natl Cancer Inst,2007,99 (4) :283-290.
  • 5Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the pre- vention of breast cancer :late results of the Italian Randomized Tamox- ifen Prevention Trial among women with hysterectomy [ J ]. J Natl Cancer Inst,2007,99 (9) :727-737.
  • 6Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized I- BIS-I trial[ J ]. J Natl Cancer Inst,2007,99 (4) :272-282.
  • 7Reimers L, Crew KD. Tamoxifen vs raloxifene vs exemestane for che- moprevention[ J]. Curt Breast Cancer Rep ,2012,4(3 ) :207-215.
  • 8Wang KL, Hsia SM, Yeh JY, et al. Anti-proliferative effects of evodia- mine on human breast cancer cells [ J ]. PLoS One, 2013,8 ( 6 ) : e67297.
  • 9王深明,马浙夫.乳腺癌的实验研究进展与热点问题[J].中华实验外科杂志,2013,30(4):655-657. 被引量:2
  • 10赵向旺,刘春萍,彭功玲,田野,郭雅文.乳腺癌细胞免疫逃逸能力的研究[J].中华实验外科杂志,2013,30(4):661-663. 被引量:3

二级参考文献12

  • 1徐茜,刘福安,吴莺,赵赟,吴剑宏,龚建平,马丁.转化生长因子-β1对乳腺癌细胞株增殖和T淋巴细胞免疫的影响[J].中华实验外科杂志,2005,22(6):695-697. 被引量:5
  • 2王深明,朱易凡.乳腺癌生物免疫治疗的临床应用研究进展与展望[J].中华实验外科杂志,2007,24(1):5-6. 被引量:5
  • 3Robinson E K, Grau A M, Evans D B, et al. Cell cycle regulation of human pancreatic cancer by tamoxifen [ J ]. Ann Surg Oncol,1998, 5(4): 342-349.
  • 4Salami S, Karami-Tehrani F. Biochemical studies of apoptosis induced by tamoxifen in estrogen receptor positive and negative breast cancer cell lines[J]. Clin Biochem, 2003, 36(4): 247-253.
  • 5Vickers SM, Jhala NC, Ahn EY, et al. Tamoxifen (TMX)/Fas induced growth inhibition of human cholangiocarcinoma (HCC) by gamma interferon (IFN-gamma) [J]. Ann Surg, 2002, 235(6):872-878
  • 6Zhang GJ, Kimijima I, Onda M, et al. Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-XL, without alteration of p53 protein levels[J].Clin Cancer Res, 1999, 5(10): 2971-2977.
  • 7Rakha EA, Chan S. Metastatic triple-negative breast cancer. Clin On- col,2011,23 : 587 -600.
  • 8Kao J, Salari K, Bocanegra M, et al. Molecular profiling of breast canc- er cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PloS One ,20(D ,4 :e61146.
  • 9Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol,2010,28:3271-3277.
  • 10Kim R, Emi M, Tanabe K. Cancer immunoediting from immune sur- veillance to immune escape. Immunology,2007,121:1-14.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部